identification cells initiating human melanomas 
tumour initiating cells capable self renewal differentiation responsible tumour growth identified human haematological malignancies solid cancers- minority populations associated tumour progression human patients specific targeting tumour initiating cells strategy eradicate cancers currently resistant systemic therapy identify subpopulation enriched human malignant melanoma initiating cells mmic defined expression chemoresistance mediator abcb5 refs show specific targeting tumorigenic minority population inhibits tumour growth abcb5+ tumour cells detected human melanoma patients show primitive molecular phenotype correlate clinical melanoma progression serial human to-mouse xenotransplantation experiments abcb5+ melanoma cells possess greater tumorigenic capacity abcb5- bulk populations re establish clinical tumour heterogeneity vivo genetic lineage tracking demonstrates specific capacity abcb5+ sub-populations self renewal differentiation abcb5+ cancer cells generate abcb5+ abcb5- progeny whereas abcb5- tumour populations give rise lower rates exclusively abcb5- cells initial proof principle analysis designed test hypothesis mmic also required growth established tumours systemic administration monoclonal antibody directed abcb5 shown capable inducing antibody dependent cell mediated cytotoxicity abcb5+ mmic exerted tumour inhibitory effects identification tumour initiating cells enhanced abundance advanced disease susceptibility specific targeting defining chemoresistance determinant important implications cancer therapy 
